Asensus Surgical, Inc. announced that Anthony Fernando, President and Chief Executive Officer and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H. C. Wainwright 24th Annual Global Investment Conference in New York City, New York.
RESEARCH TRIANGLE PARK, N.C., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Anthony Fernando, President and Chief Executive Officer and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H. C. Wainwright 24th Annual Global Investment Conference in New York City, New York. The Company’s fireside chat will take place on Monday, September 12, 2022 at 9:30 AM Eastern Time.
The H. C. Wainwright Global Investment Conference webcast will be available online on the investor relations page of the Company’s website at https://ir.asensus.com/events-and-presentations. Replay of the webcast will be archived on the website for approximately 90 days.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.
Follow Asensus
- Email Alerts: https://ir.asensus.com/email-alerts
- LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc
- Twitter: https://twitter.com/AsensusSurgical
- YouTube: https://www.youtube.com/c/transenterix
- Vimeo: https://vimeo.com/asxc
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
or
MEDIA CONTACT:
Lauren Stredler, 847-271-6891
CG Life
lstredler@cglife.com
